Drug Trials Snapshots: CAMZYOS (mavacamten)

Drug Trials Snapshots: CAMZYOS (mavacamten) CAMZYOS is a cardiac myosin inhibitor used for the treatment of symptomatic New York Heart Association (NYHA) Class II to III obstructive hypertrophic cardiomyopathy (HCM) in adults to improve functional capacity and symptoms. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-camzyos